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SUMMARY.-In vivo metabolic studies on rats and mice revealed a marked
difference in the fluorescent compounds produced after ingestion of aflatoxin
B1. The mouse converted aflatoxin B1 to three unknown fluorescent com-
pounds, designated xl, x2 and x3 and the known aflatoxin M1, while the rat was
only capable of producing aflatoxin M1. The results suggested that metabolites
X1, X2, x3 and aflatoxin M1 were not part of a major metabolic pathway, but pro-
duced independently. These unknown yellowish-green fluorescent compounds
did not seem to be conjugated with sulphate or glucuronic acid.
In vitro incubations of various mouse liver cell fractions with aflatoxin B1
showed that metabolites x,, X2, X3 and aflatoxin M1, could only be produced by
the microsomal fraction and that NADPH was needed as a co-factor. The
differences in aflatoxin metabolism by mice and rats are discussed in relation
to the apparent resistance of the mouse to the carcinogenic effects of this toxin.
AFLATOXIN B1 is acutely toxic to a number of animal species, including albino
mice, which have approximately the same susceptibility to the acute oral effects
of aflatoxin B1 (Butler, 1969) as rats (Butler, 1964). In contrast to the rat, the
mouse is resistant to the carcinogenic action of aflatoxin B1 (Platonow, 1964;
Newberne, 1965; Wogail, 1966).
It is well known that aflatoxin B1 is converted by rats to its hydroxylated
derivative, aflatoxin M1, in vivo (Patterson and Alleroft, 1970), as well as in vitro
(Schabort and Steyn, 1969). Portman et al. (1968) reported the conversion of
aflatoxin B1 to M1 by washed microsomes prepared from mouse liver, but Patterson
andAllcroft (1970) and Bassir and Emafo (1970) could not confirmthisobservation.
This study was undertaken to investigate and establish the difference between
mice and rats in their ability to convert aflatoxin B1 into fluorescent metabolites.
MATERIALS AND METHODS
All chemicals used were of analytical reagent grade. Nicotinamide-adenine
dinucleotide phosphate, reduced form (NADPH) was obtained from Boerhinger,
West Germany. Protein concentrations were determined as described by Lowry
et al. (1951). ,8-glucoronidase (bovine-liver) and aryl sulphatase (Helix pomatia)
were obtained from Calbiochem., Switzerland. 14C-Carboxyl-labelled acetate
(specific activity 25 Ci/mole) was obtained from The Radiochemical Centre,
Amersham, and used to synthesize 14C-uniformly labelled aflatoxin B1 according
to the method of Adye and Mateles (1964) and purified as described by Steyn
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Albino mice (1 23 g.) obtained from Onderstepoort Veterinary Research
Institute and our own Wistar-derived albino rats (weight ± 200 g.) were used in
these experiments.
In vivo studies
Aflatoxin B1 metabolism in mice and rats.-Two male rats (average weight
220 g.), and eight adult male mice (mean weight 23 + 2 g.) were dosedper o8 with
aflatoxin B1 (10 mg./kg.) in dimethylsulphoxide (DMSO) (0.1 ml.) and killed with
ether 2 hours later. Their livers, kidneys, stomachs plus intestines and bladders
plus urine were excised, weighed and extracted according to Purchase and Steyn
(1969), utilising an azeotrope consisting of acetone: chloroform: water
(58: 38: 4). The concentration of aflatoxin B1 was assayed according to Pons,
Robertson and Goldblatt (1966).
Absorption ofaftatoxinBlfrom thestomachs ofmnice.-Twelve male mice (average
weight 23 g.) were each dosed per os with aflatoxin B1 (10 mg./kg.) in DMSO
(0-1 ml.). Two mice were killed with ether at 2, 1, 2, 4, 6 and 71 hours after 2'2
dosing and their stomachs and intestines removed. These organs were assayed
for aflatoxin B1 as described above.
Rate of aflatoxin B1 metabolite formation in mice.-Twelve male and 12 female
mice (average weight 23 ± 2 g.) each received an oral dose of 3*0 mg. aflatoxin B
in 0*1 ml. DMSO. Two males and two females were killed as before at 20, 40, 70,
100, 150 and 180 minutes after dosing. Their livers, stomachs plus intestines,
kidneys and bladders plus urine were removed and treated as above. The relative
amounts ofthe unknown metabolites are expressed in jtg. aflatoxin B1 equivalents
as no quantitative standards ofthe unknown were available.
Two male mice (± 23 g.) each received an oral dose of 3 mg. 14C aflatoxin
B1 (30 x 103 d.p.m./mg. aflatoxin) in 0-1 ml. DMSO and were killed after 100
minutes as described before. Urine was collected from the bladders by means
of a 1 ml. syringe (total volume of urine, 0 7 ml.) and chromatographed on 1 mm.
thin-layer chromatography (t.l.c.) plates. Thefluorescent bands, containingmeta-
bolites xl, x2 and aflatoxin M1, were separately collected and the radioactivity
measured in a Beckman liquid scintillation system.
In vitro studies
Preparation of liver cell fractions.-Two adult male mice were decapitated,
their livers (total weight 6 g.) removed and homogenized in 18 ml. 0-32M sucrose-
3mM MgCl2-0.02M TRIS buffer, pH 7-6, in a Dounce homogenizer. The suspension
was centrifuged in an MSE-mistral 2 L centrifuge at 1800g for 20 minutes to
remove the nuclei, which were discarded. The supernatant was then centrifuged
at 9000g for 20 minutes in a Spinco L-4 ultracentrifuge, to yield the crude mito-
chrondrial fraction, which was suspended in 10 ml. 0-02M TRIS buffer, pH 7.4,
and kept. The microsomes were obtained by centrifugation of the resultant
supernate at 105,000g for 60 minutes, washed twice with 10 ml. of the above
mentioned buffer and diluted with the same buffer to a protein concentration of
10-15 mg. per ml. The supernatant, which consisted of the soluble cell fraction,
was used undiluted.
Incubation ofaftatoxin B1 with different cellfractions.-The incubation mixtures,
with a final volume of5 ml., were made up as follows:
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1. Aflatoxin B1 in methanol or 1,2-propylene glycol (7 mg./ml., 0 4 ml.);
2. 0*02M TRIS buffer, pH 7-4 (3.4 ml.);
3. MgCl2 solution (14.2 g./L, 0-2 ml.);
4. NADPH (74.5 mg./l ml. TRIS buffer solution): 0 5 ml.;
5. Cell fraction: 0.5 ml.
All incubations were carried out in a shaking water bath at 370 C. in cotton
wool plugged test tubes for 30 to 60 minutes. The reactions were terminated by
the addition of 10 ml. acetone. Reaction mixtures were transferred quantitatively
to suitable flasks by washing with two more 10 ml. portions of acetone.
Conjugates.-Enzyme incubations were performed as described by Fishman
(1946) and Whitehead et al. (1952), after addition of chromatographically pure
x1, x2 and x3. These metabolites were also boiled in 6N HCl for 5 minutes (Oser,
1965).
Chromatographic methods
All extracts were evaporated to dryness in a rotary evaporator (under reduced
pressure) at 450 C., and dissolved in 2 ml. benzene : acetonitrile (95 : 5). T.l.c.
plates were prepared from Camag D-5 silica gel (Camag, Switzerland), wet layer
thickness 0 5 mm., heated at 1000 C. for 2 hours and cooled at room temperature
immediately before use. After application of suitable quantities of extracts, as
well as a quantitative aflatoxin B1 standard, the chromatograms were developed
in an unlined tank containing 100 ml. chloroform : acetone (80 : 20) as the mobile
phase.
The following procedures were used to identify aflatoxin M1 in several mouse
organs:
1. T.l.c. employing four different mobile phases, namely, chloroform : acetone
(80 : 20); chloroform : methanol (95: 5); trichlorethylene acetone (10
90), and benzene ethanol : water (46: 45: 19).
2. Paper chromatography, as described by Holzapfel et al. (1966).
3. Ultra-violet spectrophotometry, employing a Beckman model DK-2A
spectrophotometer.
RESULTS
In vivo experiments
Metabolismn ofaflatoxin B1 by the mouse.-Fig. 1 illustrates the typical metabolic
conversion pattern of aflatoxin B1 by various organs of the mouse and Fig. 2
demonstrates the difference in metabolism of aflatoxin B1 between rat and mouse
livers.
From Fig. 1 and 2 it is clear that only the mouse is able to metabolize aflatoxin
B1 to three unknown fluorescent metabolites, two major and one minor, designated
xl, x2 and x3, respectively. These compounds all fluoresce green-yellowish. The
4th blue fluorescent metabolite with an Rf value between that ofxi and x2 was
shown to be chromatographically identical to aflatoxin M1 and to have a similar
ultra-violet spectrum. The rate of production of xl, x2 and aflatoxin M1 from
combined organ extracts, expressed in ,ug. aflatoxin B1 equivalents, is shown in
Fig. 3.
From Table I it is evident that metabolites x1, x2 and aflatoxin M1 recovered
from the urine of mice dosed with 14C-aflatoxin B1 are radioactive. Metabolite
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FIG. 1.-Chromatogram of metabolites extracted from various mouse organs as viewed under
ultra-violet light-1: liver; 2: stomach; 3: kidneys; 4: intestines; 5: urine plus bladder.
FIG. 2.-Chromatogram of metabolites extracted from rat and mouse liver 2 hours after
administration of aflatoxin B1. 1: rat; 2: qualitative standard containing aflatoxins B1,
M1 and B2a; 3: mouse.
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FIG. 3.-Rate of fluorescent metabolite formation in mice.
SOLVENT FRONT $~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
SOLVENT FRONT ..~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
L
294 H. PURCHASE
*:Xl; 0: MI; 0: X2-AFLATOXIN METABOLISM IN MICE AND RATS
TABLE I.-Distribution of Radioacitity in Metabolites x1, X2 and Aflatoxin Ml
in the Urine of Mice Following an Oral Dose of 14C-aflatoxin B1
Metabolite d.p.m./ml. urine
XI * 700
M1 . 1410
x2 . 3810
x3 was obtained in too low a yield to confirm its relationship to aflatoxin B1 in this
wav.
No fluorescent substances resembling B1 or its metabolites were observed in
extracts from control animals.
The ability of the mouse to absorb consistently more aflatoxin B1 from its
stomach than the rat, is illustrated in Fig. 4.
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FIG. 4.-The amounts of aflatoxin B1 detected in the stomachs of rats and mice up to 8 hours
after dosing. 0: rat; 0: mouse.
In vitro experiments
Conversion ofaflatoxinB1 byMouse livercellfractions.-The abilityofthevarious
fractions to metabolize aflatoxin B1 is illustrated in Fig. 5, which distinctly indi-
cates that only the microsomal fraction is capable of producing a variety of
fluorescent metabolites. Furthermore, it is also clear that the conversion
mechanism, present in the microsomal fraction, needs NADPH (Fig. 5).
Assay for conjugates.-Treatment of chromatographically pure xl, x2 and X3
with ,3-glucuronidase (bovine liver) aryl sulphatase (Helix pomatia) or 6N HC1
showed no effect.
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FIG. 5.-The ability ofmouse liver cell fractions to convert aflatoxin B1. 1: cell sap; 2: crude
mitochondrial fraction; 3: qualitative standard containing aflatoxins B1, M1 and B2a; 4:
microsomal fraction plus NADPH; 5: microsomal fraction without NADPH.
DISCUSSION
When a comparison is made between the amount of aflatoxin B1 in rat and
mouse stomachs after a single dose, it is clear that the mouse absorbs the toxin
more quickly than the rat. As the acute toxicity in the mouse and rat are
approximately the same, the mouse must either be more resistant to the effects
ofthe toxinper se or it must be able to metabolize (detoxify) the toxin at a greater
rate than the rat. The ability of the mouse to produce numerous fluorescent
metabolites, and the absence oflarge quantities ofaflatoxin B1 in liver andkidneys
indicate that the mouse is capable of metabolizing aflatoxin efficiently.
The absence of carcinogenicity of aflatoxin in mice may also be related to the
rapid metabolism. Alternatively, ifaflatoxin B1 is converted into an " ultimate "
carcinogen by metabolism in the rat, the lack ofcarcinogenicity couldbe due to the
different metabolic conversion products produced by the mouse. Further studies
on the identity and biological activity ofaflatoxin metabolites may indicate which
of these two suggestions is correct.
The in vitro experiments clearly indicate that only the microsomal fraction of
mouse liver contains the enzyme(s) necessary for the conversion of aflatoxin B1
to M1 and the other three fluorescent components.
In addition, it is also possible that the cytochrome P-450 component, which
is the rate-limiting step in drug conversion ofmouse liver microsomes, has a higher
affinity for aflatoxin B1 than that ofthe rat. Since we accept the observation that
the mouse is resistant to aflatoxin B1-induced carcinogenicity, the conversion of
aflatoxin B1 to the three fluorescent compounds could be used as a monitoring
system to study the susceptibility of various animal species, including man, to
aflatoxin B1-inducible carcinogenesis. Obviously, much more work has still to
be done to validate such a statement.
Although highly unlikely, the possibility existed that the metabolites xl, x2
and aflatoxin M1 were formed in mice through the synergistic action of aflatoxin
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B1 and DMSO from some other compound normally present in the animals. This
possibility was exluded by using 14C-aflatoxin B1 (Table I).
Whether aflatoxin M1, metabolites xl, x2 and x3 are minor metabolites or
intermediates in a major metabolic pathway in the mouse cannot be deduced
from our results. However, the results in Fig. 3 suggest that these metabolites
are synthesized independently, since their excreted concentrations are similar at
any particular time. Both mouse and rat livers could also metabolize aflatoxin B1
to non-fluorescent compounds which are not perceptible, or to fluorescent meta-
bolites which are not extracted with the acetone: chloroform: water azeotrope.
It also seems that xl, x2 and X3 are not glucuronide or sulphate conjugates.
The results of this study clearly demonstrate that the mouse can hydroxylate
aflatoxin B1 to aflatoxin M1. This is in agreement with the results from Portman
et al. (1968) who suggested that mouse liver microsomes hydroxylate aflatoxin
B1 (forming M1) faster than those of rat liver. However, these authors did not
mention the presence of other fluorescent components. Although Bassir and
Emafo (1970) failed to demonstrate M1 production by mouse liver, they did des-
cribe the presence of a green-yellow fluorescent substance. Whether their
unknown fluorescent compound corresponds with our xl, x2 or X3 is at present
unknown. These differences couldbe due to different strains ofmice or to different
extraction techniques used by the various authors.
The authors wish to thank Mr. N. P. Ferreira of the Microbiology Research
Group, C.S.I.R., Pretoria, Republic of South Africa, for the production of
14C-aflatoxin B1.
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